StreetInsider.com News Articles

Form 4 BRISTOL MYERS SQUIBB CO For: Sep 01 Filed by: Short Bartie Wendy

Thu, 03 Sep 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260903/27025141.html

BMS presents five-year Camzyos data for heart condition at ESC

Mon, 31 Aug 2026 06:05:10 -0400

Bristol Myers Squibb (NYSE: BMY) presented results from the EXPLORER-LTE cohort of the MAVA-LTE study at the European Society of Cardiology Congress 2026 in Munich, Germany, showing sustained efficacy and safety of Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) over up to five years.

EXPLORER-LTE is a single-arm, open-label extension of the Phase 3 EXPLORER-HCM study, enrolling 231 patients from the United States, Europe, and Israel. At 252 weeks, patients showed mean reductions from baseline of 38.7 mm Hg in resting left ventricular outflow tract (LVOT) gradient and 55.6 mm Hg in Valsalva LVOT gradient. Nearly all patients

BMS presents five-year Camzyos data for heart condition at ESC

Mon, 31 Aug 2026 06:05:10 -0400

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European

Sat, 29 Aug 2026 11:00:00 -0400

Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings

Form 4 BRISTOL MYERS SQUIBB CO For: Aug 25 Filed by: Holzer Phil M

Wed, 26 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260826/26982058.html

Form 4 BRISTOL MYERS SQUIBB CO For: Aug 25 Filed by: Holzer Phil M

Wed, 26 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260826/26982058.html

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

Wed, 26 Aug 2026 09:20:00 -0400